


29-29-05

AF
JFW

AGILENT TECHNOLOGIES, INC.
Legal Department, DL429
Intellectual Property Administration
P. O. Box 7599
Loveland, Colorado 80537-0599



ATTORNEY DOCKET NO. 10003511-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Paul K. Wolber

Serial No.: 09/628,472

Examiner: B. Forman

Filing Date: July 31, 2000

Group Art Unit: 1634

Title: ARRAY BASED METHODS FOR SYNTHESIZING NUCLEIC ACID MIXTURES

COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria VA 22313-1450

TRANSMITTAL OF APPEAL BRIEF

Sir:

Transmitted herewith is the Appeal Brief in this application with respect to the Notice of Appeal filed on 10-04-2004 and the Notification of Non-Compliant Appeal Brief dated 9-19-05.

The fee for filing this Appeal Brief is (37 CFR 1.17(c)) \$500.00. paid on 1-4-05
(complete (a) or (b) as applicable)

The proceedings herein are for a patent application and the provisions of 37 CFR 1.136(a) apply.

☐ (a) Applicant petitions for an extension of time under 37 CFR 1.136 (fees: 37 CFR 1.17(a)(1)-(5)) for the total number of months checked below:

<input type="checkbox"/>	one month	\$ 120.00
<input type="checkbox"/>	two months	\$ 450.00
<input type="checkbox"/>	three months	\$1020.00
<input type="checkbox"/>	four months	\$1590.00

☐ The extension fee has already been filled in this application.

☒ (b) Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

Please charge to Deposit Account 50-1078 the sum of _____. At any time during the pendency of this application, please charge any fees required or credit any overpayment to Deposit Account 50-1078 pursuant to 37 CFR 1.25.

A duplicate copy of this transmittal letter is enclosed.

EX-1005 MAIL NUMBER
EV687633478WS

☒ I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit: 09-27-2005 OR

☐ I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Date of Facsimile:

Typed Name: Donna Macedo

Signature: 

Respectfully submitted,

Paul K. Wolber

By 

Bret E. Field for Dianne Rees
Attorney/Agent for Applicant(s)

Reg. No. 37,620

Date: 09-27-2005

Telephone No. (650) 485-5999



AF

Express Mail No.

EV687633478US

APPELLANTS' BRIEF Address to: Mail Stop Appeal Brief-Patents Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	10003511-1
	First Named Inventor	Paul K. Wolber
	Confirmation Number	1634
	Application Number	09/628,472
	Filing Date	July 31, 2000
	Group Art Unit	1634
	Examiner Name	B. Forman

Sir:

This Brief is filed in response to the Notice of Non-Compliant Appeal Brief dated September 19, 2005 for which a one month period for response was given. As such, this Appeal Brief is timely filed.

In response to the Notice of Notice of Non-Compliant Appeal Brief, the Applicants have added an Evidence Appendix and Related Proceedings Appendix, as requested.

This Brief is filed in support of Appellants' appeal from the Examiner's Rejection dated June 3, 2004. No claims have been allowed, and claims 1-15 and 21-23 are pending. Claims 1-15 and 21-23 are appealed. A Notice of Appeal was filed on October 4, 2004.

The Board of Appeals and Interferences has jurisdiction over this appeal pursuant to 35 U.S.C. §134.

The Commissioner is hereby authorized to charge deposit account number 50-1078, reference no. 10003511-1 to cover the fee required under 37 C.F.R. §1.17(c) for filing Appellants' brief. In the unlikely event that the fee transmittal or other papers are separated from this document and/or other fees or relief are required, appellants petition for such relief, including extensions of time, and authorize the Commissioner to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to deposit account number 50-1078, reference no. 10003511-1.

09/30/2005 ZJUHA1 00000051 501078 09628472

01 FC:1452 500.00 DA

10/03/2005 ZJUHA1 00000091 501078 09628472

01 FC:1402 500.00 DA

TABLE OF CONTENTS

<u>CONTENTS</u>	<u>PAGE</u>
REAL PARTY IN INTEREST.....	3
RELATED APPEALS AND INTERFERENCES.....	3
STATUS OF CLAIMS.....	3
STATUS OF AMENDMENTS	3
SUMMARY OF THE CLAIMED SUBJECT MATTER.....	4
GROUND OF REJECTION TO BE REVIEWED ON APPEAL	7
ARGUMENTS	8
SUMMARY.....	18
RELIEF REQUESTED	19
APPENDIX I (APPEALED CLAIMS).....	20
EVIDENCE APPENDIX.....	25
RELATED PROCEEDINGS APPENDIX.....	26

REAL PARTY IN INTEREST

The inventors named on this patent application assigned their entire rights to the invention to Agilent Technologies, Inc.

RELATED APPEALS AND INTERFERENCES

There are currently no other appeals or interferences known to Appellants, the undersigned Appellants' representative, or the assignee to whom the inventors assigned their rights in the instant case, which would directly affect or be directly affected by, or have a bearing on the Board's decision in the instant appeal.

STATUS OF THE CLAIMS

The present application was filed on July 31, 2000 with claims 1-20. Claims 1-20 were subjected to a restriction requirement and on August 6, 2001 a provisional election was made with traverse to prosecute the invention of Group I, Claims 1-15. During prosecution of the application, Claims 16-20 were cancelled and new Claims 21-23 were added. Accordingly, Claims 1-15 and 21-23 are pending in the present application and are appealed herein.

All of the pending Claims 1-15 and 21-23 shown in the attached Appendix remain pending, rejected, and appealed herein.


STATUS OF AMENDMENTS

During the course of prosecution, amendments were filed on February 4, 2002, amending Claims 1, 5, 8, 14 and 15, which amendments were entered. Amendments were filed on July 3, 2002, amending Claims 1 and 5, which amendments were entered. On February 3, 2003 an amendment was filed amending Claim 1, which amendment was entered. On August 18, 2003 an amendment was filed amending Claims 1 and 5, which amendment was entered. On March 24, 2004, an amendment was filed amending Claims 1, 4, 5 and 9, canceling withdrawn Claims 16-20 and adding Claims 21 to 23, which amendment was entered. Thus, Claims 1-15 and 21-23 are pending and appealed, which claims are recited in the attached Appendix.

SUMMARY OF THE CLAIMED SUBJECT MATTER


The pending claims of the application are directed to methods of producing mixtures of single stranded nucleic acids of differing sequence using a template array. (Specification, page 4, lines 20-25). The nucleic acid mixtures produced by the subject methods (among other utilities) find use as gene specific primers in differential gene expression analysis applications. (Specification, page 13, lines 18-21).

With respect to the invention as claimed in first independent Claim 1, this claim is directed to a method having four recited steps. The first step of the claim is to provide an array of distinct single stranded nucleic acids of differing sequence. (Specification, page 5, lines 6-9). In the provided array, all of the distinct single stranded nucleic acids are immobilized on the same surface of a substrate. (Specification, page 5, lines 6-9) Furthermore, each distinct single stranded nucleic acid immobilized on the surface of the substrate has a constant domain and a variable domain (Specification, page 5, lines 19-31), where the variable domain is positioned at the 5' end of the nucleic acid (Specification, page 8, line 16). Below is an illustration of the array provided in this step:



In the next step of the method claimed in first independent Claim 1, nucleic acids complementary to the constant domains of the single stranded nucleic acids of the provided array are hybridized to the constant domains to produce a template array. (Specification, page 9, line 33 to page 10, line 3). The produced template array is characterized by having on its surface nucleic acids that include a double-stranded region and a single-stranded region. In other words, the nucleic acids immobilized on the surface of the duplex array are overhang

comprising nucleic acids having a double-stranded region and a single-stranded region. (Specification, page 10, lines 2-3 and 17-24). The double-stranded region includes the constant domain of the original nucleic acids of the array provided in the first step, while the single-stranded region includes the variable domain of the original nucleic acids of the array provided in the first step. Below is an illustration of the template array provided in this step:



In the next step of the method of first independent claim 1, the template array provided by the second step is subjected to a cyclic reaction that produces a mixture of linearly amplified amounts of single-stranded nucleic acids of differing sequence. Examples of the conditions to which the template array is subjected in this step include: linear PCR; strand displacement amplification and in vitro transcription. (Specification, page 10, lines 30 to 33). The conditions to which the template array is subjected are conditions that produce a mixture of single-stranded nucleic acids of differing sequence. (Specification, page 13, lines 1 to 6). The term "mixture" has its common meaning as defined in the online dictionary available at:

<http://dictionary.reference.com/search?q=mixture>

as:

- 1) One that consists of diverse elements; or
- 2) A composition of two or more substances that are not chemically combined with each other and are capable of being separated.

As such, the term mixture means a heterogeneous composition of two or more distinct substances, e.g., two or more different nucleic acids of differing sequence, that are not separated from each other.

In the final step of the method of Claim 1, the product mixture is separated from the template array, e.g., for subsequent use as a gene specific primer mixture. Because the product mixture is separated from the template array, it is not immobilized on a surface of a solid support, but instead is a fluid composition of a mixture of single stranded nucleic acids of differing sequence.

Independent Claim 5 claims a method analogous to Claim 1, but further specifies the different elements of the surface immobilized nucleic acids and primers employed in the claimed methods. For example, Claim 5 specifies that the surface immobilized nucleic acids of the array provided in the first step are ones that include a functional domain and a recognition domain. The embodiments of independent Claim 5 are described in the specification at page 8, line 15 to page 10, line 24. Dependent Claim 7 specifies that the functional domain is an RNA polymerase promoter domain. (Specification, page 7, lines 23-29). This particular embodiment is employed in methods where in vitro transcription reaction conditions are used to generate a product mixture from the template array. (Specification, page 12, lines 16-30). Dependent Claim 8 specifies that recognition domain is a domain having a sequence cut by a restriction endonuclease. (Specification, page 8, lines 1-7).

Independent Claim 10 is directed to methods of generating target nucleic acids, e.g., for use in a differential gene expression analysis application. (Specification, page 13, line 18 to page 15, line 20). The method is characterized by including a first step of generating a primer composition, where the primer composition generation protocol is the protocol of Claim 1. Dependent Claim 11 specifies that the target generation step includes a primer extension reaction, e.g., as described in the specification at page 14, lines 14 ff. Dependent Claim 12 specifies that the protocol results in labeled target nucleic acids, e.g., as described in the Specification at page 15, lines 14-20.

Independent Claim 13 is directed to a hybridization assay, in which a nucleic acid sample is contacted with an array of nucleic acids. (Specification at page 15, line 24 to page 16, line 3). A feature of the method of Claim 13 is that the target population employed the method is a target population prepared according to the method of Claim 10. In the claimed

method, a target population of nucleic acids as prepared in Claim 10 is contacted with an array of probe nucleic acids (i.e., that is different from the initial array and template array), and any resultant duplexes on the surface of the array are detected.

Independent Claim 21 is analogous to independent Claim 1, but is specifically directed to the embodiment in which the product mixture of nucleic acids is produced from the template array by an in vitro transcription reaction. This embodiment is described in the specification at page 12, lines 16 to 30.

Independent Claim 22 is analogous to independent Claim 1, but is specifically directed to the embodiment in which the product mixture of nucleic acids is produced from the template array by linear PCR reaction. This embodiment is described in the specification at page 11, lines 1-31.

Independent Claim 23 is analogous to independent Claim 1, but is specifically directed to the embodiment in which the product mixture of nucleic acids is produced from the template array by strand displacement amplification reaction. This embodiment is described in the specification at page 11, line 32 to page 12, line 15.

· GROUND S OF REJECTION TO BE REVIEWED ON APPEAL

I. Claims 1-9 and 21-22 stand rejected under 35 U.S.C. § 103(a) as being obvious over U.S. Patent No. 4,734,363 and U.S. Patent No. 5,652,099.

II. Claims 10-15 stand rejected under 35 U.S.C. § 103(a) as being obvious over U.S. Patent No. 4,734,363 and U.S. Patent No. 5,652,099 and further in view of U.S. Patent No. 5,795,714.

III. Claim 23 stands rejected under 35 U.S.C. § 103(a) as being obvious over U.S. Patent No. 4,734,363 and U.S. Patent No. 5,652,099 and further in view of U.S. Patent No. 5,215,899.

ARGUMENTS

- I. Rejection of Claims 1-9 and 21-22 under 35 U.S.C. § 103(a) as being obvious over U.S. Patent No. 4,734,363 and U.S. Patent No. 5,652,099.

In the Advisory Action, the Examiner maintained the rejection of Claims 1-9 and 21-22 under 35 U.S.C. § 103(a) as being obvious over U.S. Patent No. 4,734,363 (hereinafter the '363 patent) and U.S. Patent No. 5,652,099 (hereinafter the '099 patent). In first making this rejection, the Examiner asserted that because Dattagupta discloses a template dependent polymerase mediated reaction "for producing a mixture of nucleic acid" in which the template is bound to the surface of a bead and Conrad teaches a method in which different plasmids are subjected to reaction conditions that produce a mixture of product nucleic acids from the different plasmids, the claimed invention is obvious.

With respect to rejections made under 35 U.S.C. § 103, the MPEP § 2142 states that:

To establish a *prima facie* case of obviousness, three basic criteria must be met. First, **there must be some suggestion or motivation**, either in the references themselves or in the knowledge generally available to one of ordinary skill in the art, **to modify the reference or to combine reference teachings**. Second, there must be a reasonable expectation of success. Finally, the prior art reference (or references when combined) must teach or suggest all the claim limitations. **The teaching or suggestion to make the claimed combination and the reasonable expectation of success must both be found in the prior art, and not based on applicant's disclosure.** *In re Vaeck*, 947 F.2d 488, 20 USPQ2d 1438 (Fed. Cir. 1991). [emphasis added]

It is respectfully submitted that the Examiner's *prima facie* case of obvious is deficient because:

- A) the cited references have been impermissibly combined using only the Applicants' disclosure as the motivation; and
- B) even if the teaching of the references are combined, the combined teaching fails to teach or suggest the invention as claimed.

Each of these above summarized deficiencies in the Examiner's *prima facie* case of obviousness is now reviewed in greater detail below.

A) Use of impermissible hindsight in combining the '363 and '099 patents

As summarized above, the MPEP teaches that the Applicants' disclosure cannot be employed for motivation to combine the teaching of two references. Specifically, MPEP § 2143.01 states that:

The mere fact that references can be combined or modified does not render the resultant combination obvious unless the prior art also suggests the desirability of the combination. *In re Mills*, 916 F.2d 680, 16 USPQ2d 1430 (Fed. Cir. 1990).

Furthermore, the MPEP § 2143.01 states that:

A statement that modifications of the prior art to meet the claimed invention would have been " 'well within the ordinary skill of the art at the time the claimed invention was made' " because the references relied upon teach that all aspects of the claimed invention were individually known in the art is not sufficient to establish a *prima facie* case of obviousness without some objective reason to combine the teachings of the references. *Ex parte Levengood*, 28 USPQ2d 1300 (Bd. Pat. App. & Inter. 1993). See also *In re Kotzab*, 217 F.3d 1365, 1371, 55 USPQ2d 1313, 1318 (Fed. Cir. 2000)

As further explained below, the Examiner has combined elements of the prior art in an impermissible manner.

In combining the teachings of the references, the Examiner states that: "It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to modify the probe synthesis of Dattagupta et al by immobilizing additional nucleic acids of different sequences for the expected benefit of proving various types of diagnostics based and further based on the broad importance of probe cocktails as taught by Conrad. "

However, the '363 patent only describes a single type of template immobilized on a given solid support. This is an important feature of the asserted utility of the '363 patent in

that the structure is a sensitive probe for a single nucleic acid analyte. One of skill in the art would not be motivated to modify the beads of the method disclosed in the '363 patent to each display two or more different templates because then one would not be able to use the structure to detect a single analyte, but just the presence of at least one of two or more different analytes. As taught by the MPEP, a proposed modification of a prior art invention "cannot render the prior art invention being modified unsatisfactory for its intended purpose" (See MPEP2143.01 and *In re Gordon*, 733 F.2d 900, 221 USPQ 1125 (Fed. Cir. 1984)).

Furthermore, one would not be motivated to modify the method disclosed in the '099 patent such that multiple plasmids are replaced with bead bound nucleic acids. One of skill in the art would not be so motivated because access of the polymerase enzymes to the template nucleic acid could potentially be hindered if the template DNA were immobilized on a solid support surface. As such, providing the template DNA immobilized on a solid support surface as opposed to in a plasmid form in solution would potentially provide substandard results, without any potential benefit. As such, one of skill in the art would not be motivated to modify the '099 method so that the plasmid templates were replaced with surface immobilized templates.

As such, a motivation to combine the references of the '363 and '099 patents does not exist in the art as cited, contrary to the assertion of the Examiner.

Accordingly, the only motivation that is present to combine the teaching of the '363 and '099 patents is the present application. As reviewed above, using an application as motivation for combining references amounts to the use of impermissible hindsight, and is not sufficient to support a combination of references.

In the Advisory Action, the Examiner asserts that the combination of the '363 and '099 patents is proper, citing to *In re McLaughlin*, 170 U.S. P.Q. 209, which states that:

"the test for combining references is not what the individual references themselves suggest but rather what the combination of disclosures taken as a whole would suggest to one of ordinary skill in the art. Any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning, but so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made and does not include knowledge gleaned only from applicant's disclosure, such a reconstruction is proper. "

However, the combination of the references taken as whole would not suggest combining the teachings of the references as the Examiner has done. Specifically, one would not modify the '099 disclosure such that the templates were present on a substrate, because of the potential substandard reactions that could have been achieved. These substandard reactions would have been potentially realized without any perceived benefit in view of the utilities asserted in the '099 patent, or the '363 patent. Furthermore, modifying the '363 patent pursuant to the '099 patent would have rendered the protocol of the '363 patent inoperable for its intended purpose, i.e., to detect a single nucleic acid analyte. As such, only with Applicants' asserted utilities, e.g., to make populations of different nucleic acids (for example for use as gene specific primers), would one be motivated to combine these references. As such, the references have been combined with knowledge gleaned only from the Applicants' disclosure, and therefore have been impermissibly combined.

Therefore, since the teachings of the '363 and '099 patents have been impermissibly combined, the Examiner's prima facie case of obvious is defective and should be withdrawn.

B) The Combined Teaching of the References Fails to Teach or Suggest all of the Elements of the Claimed Invention

As reviewed above, even if the teachings of two or more references are properly combined, they must teach or suggest all of the elements of claimed invention in order to render a claimed invention prima facie obvious.

As reviewed above, the claimed invention is directed to methods of producing **mixtures** of nucleic acids. Applicants first point out that the term "mixture" is used in its ordinary meaning, as defined in the online dictionary, available at:

<http://dictionary.reference.com/search?q=mixture>

as:

- 1) One that consists of diverse elements; or
- 2) A composition of two or more substances that are not chemically combined with each other and are capable of being separated.

As such, the term "mixture" means a heterogeneous composition of two or more distinct substances, e.g., two or more different nucleic acids of differing sequence, where each constituent member of the mixture is not physically separated from the other constituents of the mixture.

The '363 patent describes a method in which a single template is bound to the surface of a bead and then employed in a primer extension reaction to produce a single type of nucleic acid. As such, it is incorrect to characterize the '363 patent as a method of producing a "mixture" of nucleic acids (contrary to the Examiner's reading of the '363 patent). In fact, since the '363 patents' described utility is to detect a single nucleic acid analyte using the bead bound template, one would not find any suggestion or teaching in the '363 patent of a method that produces a "mixture" of nucleic acids. Accordingly, to the extent that the Examiner's prima facie case of obviousness is based on this incorrect reading of the '363 patent, the rejection should be withdrawn.

The Examiner asserts in the Advisory Action that the '363 disclosed protocol is incomplete and therefore produces a mixture of nucleic acids. It is not seen where in the '363 disclosure such a teaching of incomplete reactions is made, and the Examiner has cited no supplemental references demonstrating that such occurs in the '363 patent.

In addition, the Examiner points out in the Advisory Action that the '099 patent does teach production of a mixture. It is noted however that the Final Rejection looked to the '363 patent as teaching production of a mixture, not the '099 patent.

To the extent that the '099 patent does teach production of a mixture, such is incompatible with the teaching of the '363 patent in view of the purpose of the '363 methods. As such, the combined teachings of the '099 and '363 patents do not teach a method to produce a mixture.

Furthermore, the claimed invention includes the limitation that one employ:

an array of distinct single-stranded probe nucleic acids of differing
sequence immobilized on a substrate

Because the probe nucleic acids of differing sequence must be immobilized on a substrate, i.e., a single substrate, one of skill in the art, in view of the of the specification, reads the limitation as requiring a structure that is made up of a substrate which includes the distinct nucleic acids immobilized at different and known locations on the surface of the support.

Turning now to the cited references, nowhere in the combined teaching of these references is an array structure as required in the claimed methods taught or suggested. Specifically, the cited combination of references fails to teach or suggest a method that employs a plurality of distinct nucleic acids immobilized on a surface of a **single** solid support.

Accordingly, the combined teachings of the references fail to teach or suggest all of the elements of the claimed invention, i.e., a method that employs a plurality of distinct nucleic acids immobilized on a surface of a **single** solid support.

In the Advisory Action, the Examiner rejects this reasoning by stating:

"Applicant argues that the cited reference do not teach every element of the claims because they do not teach 'a single substrate' having immobilized probes of differing sequence. The argument has been considered but is not found persuasive because as stated above, the claims do not require the differing probes be immobilized to the same i.e. a single substrate. Hence the argument is not commensurate in scope with the claims."

However, as pointed out above, the claims do include the limitation that the array be:

an array of distinct single-stranded probe nucleic acids of differing sequence immobilized on a substrate

As such, the Examiner's reasoning for rejecting this position is faulty in that the claims are limited to an array of nucleic acids of differing sequence immobilized on a single substrate.

As such, the combined teaching of the '363 and the '099 patents fails to teach or suggest the invention as claimed, since the combined teaching fails to teach or suggest at least the claim elements of producing a mixture of nucleic acids and employing an array of different single stranded nucleic acids present on the same surface of a solid support.

C) Conclusion with respect to Claims 1-9 and 21-22

The Examiner's prima facie case of obvious with respect to Claims 1-9 and 21-22 is deficient because:

- 1) the cited references have been impermissibly combined using only the Applicants disclosure as the motivation; and
- 2) even if the teaching of the references are combined, the combined teaching fails to teach or suggest the invention as claimed.

As such, Claims 1-9 and 21-22 are not obvious under 35 U.S.C. § 103(a) over the '363 patent in view of the '099 patent and this rejection may be withdrawn.

II. Rejection of Claims 10-15 under 35 U.S.C. § 103(a) as obvious over U.S. Patent No. 4,734,363 and U.S. Patent No. 5,652,099 and further in view of U.S. Patent No. 5,795,714.

Claims 10-15 stand rejected as obvious under 35 U.S.C. § 103(a) over the '363 patent and '099 patent and further in view of U.S. Patent No. 5,795,714 (hereinafter the '714 patent).

Appellants request that Claims 13 - 15 be considered separately from Claims 10-12 and therefore provide arguments separately below to each of these two groups.

A. Claims 10-12

As reviewed above, one would not combine the teachings of the '363 and '099 patents. Furthermore, one would not combine the teachings of the '714 patent with at least the '099 patent because, while the '099 patent may teach producing a mixture of nucleic acids, the '714 patent specifically teaches away from producing a mixture of nucleic acids.

The '714 patent discloses methods in which “master” arrays are used as templates for the production of new duplicate arrays. The disclosed methods in the '714 patent, including those in which the synthesized nucleic acids are in suspension, require that the distinct synthesized nucleic acids from the template array remain separated from each other. In the preferred embodiments of the '714 patent, in which duplicate arrays are fabricated from the “master” array, the synthesized nucleic acids must also maintain their spatial integrity with respect to each other such that when they are subsequently immobilized onto a substrate, a functional array is produced. Because the '714 patents' method is based on keeping synthesized nucleic acids separate from each other, one of skill in the art would have no motivation to combine the '714 patent with the '099 patent. As such, this prima facie case of obvious is deficient for at least this reason.

Furthermore, as demonstrated above, the combined teaching of the '363 patent and the '099 patent fails to teach or suggest the element of the claimed invention that requires use of an array of distinct nucleic acids immobilized to a surface of a single solid support.

While the '714 patent may teach an array structure, as pointed out above, the '714 patent teaches such for use as a master array for the production of replicate arrays, and the method requires that the product nucleic acids be kept separate from each other and employed as probes on the replicate arrays.

Since it is well settled that a proposed modification of a prior art invention "cannot render the prior art invention being modified unsatisfactory for its intended purpose" (See MPEP2143.01 and *In re Gordon*, 733 F.2d 900, 221 USPQ 1125 (Fed. Cir. 1984)), if one were to combine the '363 patent with the '099 patent and '714 patent, one would arrive at a method in which product nucleic acids are kept separate from each other, since a method that produced a mixture would render both the '714 and '363 methods unsatisfactory for their intended purpose. As such, one would arrive at a method in which the product is not a mixture of nucleic acids, but instead a collection of physically separated distinct nucleic acids.

As reviewed above, an element of the claimed methods is that they produce a **mixture** of nucleic acids. Accordingly, the combined teaching of the '363, '099 and '714 patent does not teach this element of the claimed methods.

Furthermore, the methods of Claims 10-12 require an additional step of using the product mixture in the generation of a population of target nucleic acids by using the initial product mixture as primer in a template dependent reaction. Nowhere in the combined teachings of the '363, '099 and '714 patents is such a step taught or suggested. Specifically, the '363 and '099 patents are not concerned with using their product nucleic acids as an intermediate in a subsequent reaction, much less a target generation reaction. Furthermore, contrary to the Examiner's reading, the product nucleic acids of the '714 disclosed method are used as probe nucleic acids in a replicated array, not as primers to

generate target nucleic acids. As such, the combined teachings of the references fails to disclose this additional step of the claimed methods in which the product nucleic acids are used in a primer extension reaction to produce target nucleic acids.

Since the combined teaching of the '363 patent in view of the '099 patent and further in view of '714 patent does not teach a method that:

- 1) produces a mixture of nucleic acids; and
- 2) uses the product mixture to produce target nucleic acids;

Claims 10 -12 are not obvious under 35 U.S.C. § 103(a) over these references and this rejection may be withdrawn.

B. Claims 13-15

With respect to Claims 13 -15, these claims are even further distinguished from the combined teaching of the '363, '099 and '714 patents. As reviewed above, Claim 13 requires that the product target nucleic acids produced by the method of Claim 10 be contacted with an array of probe nucleic acids.

In contrast to this step, the '714 patents' disclosed method is directed to making nucleic acids that are used as probes and immobilized on a support to produce a replicate array of a master, and as such the product nucleic acids are not contacted with an array of probe nucleic acids. Put another way, the product nucleic acids of the '714 patent, or for that matter the '363 and the '099 patents, are not contacted with an array of nucleic acids.

Accordingly, none of the cited '363, '099 and '714 patents, either alone or in combination, teach a step of contacting a product mixture of nucleic acids with an array of nucleic acids, as is claimed in Claims 13 to 15. Accordingly, the combined teachings of the '363, '099 and '714 patents fails to teach or suggest at least this element of Claims 13-15 and therefore the rejection of Claims 13-15 as obvious over the '363, '099 and '714 patents may be withdrawn.

III. Rejection of Claim 23 under 35 U.S.C. § 103(a) as obvious over U.S. Patent No. 4,734,363 and U.S. Patent No. 5,652,099 and further in view of U.S. Patent No. 5,215,899.

Claim 23 has been rejected under 35 U.S.C. § 103(a) as being obvious over the '363 and '099 patents and further in view of U.S. Patent No. 5,215,899 (hereinafter the '899 patent).

As reviewed above, the combination of the '363 and '099 patents represents an impermissible combination of references that, even if combined, fails to teach or suggest the elements of the claimed invention that requires:

- (1) the use of an array of distinct nucleic acids immobilized to a surface of a solid support; to
- (2) produce a mixture of nucleic acids.

As the '899 patent has been cited solely for the concept of employing a strand displacement amplification protocol, the '899 patent fails to make up the deficiency in the teachings of the primary references.

Accordingly, Claim 23 is not obvious under 35 U.S.C. § 103(a) over the '363 and '099 patents in view of the '899 patent and this rejection may be withdrawn.

SUMMARY

- 1-9 and 21-22 are patentable under 35 U.S.C. § 103(a) over the '363 and the '099 patents. As described above, there is no motivation to combine the references. Furthermore, even if the references are combined, the combined teaching fails to teach or suggest at least the elements of using an array of nucleic acids to produce a mixture of nucleic acids.

- Claims 10-12 are patentable under 35 U.S.C. §103(a) over the '363, '099 and '714 patents for reasons described above and because the cited references fail to teach or suggest generating a mixture of nucleic acids from an initial mixture of nucleic acids producing using a template array.
- Claims 13-14 are patentable under 35 U.S.C. §103(a) over the '363, '099 and '714 patents for reasons described above and because the cited references fail to teach or suggest contacting a mixture of nucleic acids produced by the method of Claim 10 with an array.
- Claim 23 is patentable under 35 U.S.C. §103(a) over the '363 and '099 patents in view of the '899 patent for reasons described above.

RELIEF REQUESTED

Appellants respectfully request that the rejections of Claims 1-15 and 21-23 under 35 U.S.C. §103 be reversed, and that the application be remanded to the Examiner with instructions to issue a Notice of Allowance.

Respectfully submitted,

Date: September 27, 2005

By: 

Bret Field
Registration No. 37,620

AGILENT TECHNOLOGIES, INC.
Legal Department, DL429
Intellectual Property Administration
P.O. Box 7599
Loveland, Colorado 80537-0599

APPENDIX OF APPEALED CLAIMS

1. A method for producing a mixture of nucleic acids, said method comprising:
 - (a) providing an array of distinct single-stranded probe nucleic acids of differing sequence immobilized on a substrate where each distinct probe present on said array comprises a constant domain and a complement variable domain; wherein said complement variable domain is at the 5' end of said each distinct probe;
 - (b) hybridizing nucleic acids complementary to said constant domain with said array of single-stranded probe nucleic acids to produce a template array of overhang comprising duplex nucleic acids, wherein each overhang comprising duplex nucleic acid of said array comprises a double-stranded constant region and a single-stranded variable region overhang;
 - (c) subjecting said template array of overhang comprising duplex nucleic acids to a cyclic reaction that produces a mixture of linearly amplified amounts of single stranded nucleic acids of differing sequence; and
 - (d) separating said mixture of nucleic acids from said template array.
2. The method according to Claim 1, wherein said mixture of nucleic acids is a mixture of deoxyribo-oligonucleotides.
3. The method according to Claim 1, wherein said constant domain comprises at least one domain selected from the group consisting of: a linker domain; a functional domain; and a recognition domain.
4. The method according to Claim 1, wherein said step (c) comprises a protocol selected from the group consisting of: linear PCR; and strand displacement amplification.
5. A method for producing a mixture of a plurality of distinct deoxyribo-oligonucleotides of differing sequence, wherein each distinct deoxyribo-oligonucleotide of said plurality comprises a different variable domain V, said method comprising:
 - (a) providing an array of a plurality of substrate surface immobilized distinct

single-stranded probes, wherein each distinct surface immobilized single-stranded probe present on said array is described by the formula:



wherein:

L is an optional linking domain;

R is a recognition domain;

F is a functional domain; and

cV is a complement domain having a sequence that hybridizes under stringent conditions to a variable domain of one of said distinct oligonucleotides of said plurality;

(b) contacting said array of a plurality of surface immobilized distinct single-stranded probes under hybridization conditions with a population of nucleic acids of the formula:



wherein:

cR is the complement of R; and

cF is the complement of F;

whereby a template array of overhang comprising duplex nucleic acids is produced, wherein each overhang comprising duplex nucleic acid of said array is described by the formula:



(c) subjecting said template array of overhang comprising duplex nucleic acids to a cyclic reaction that produces a mixture of linearly amplified amounts of single stranded nucleic acids of differing sequence; and

(d) separating said mixture of nucleic acids from said template array, to produce said mixture of a plurality of distinct deoxyribo-oligonucleotides of differing sequence, wherein each distinct constituent of said plurality comprises a different variable domain V.

6. The method according to Claim 5, wherein said linker domain ranges in length from about 0 to 10 bases.
7. The method according to Claim 5, wherein said functional domain is an RNA polymerase promoter domain.
8. The method according to Claim 5, wherein said recognition domain is recognized by a restriction endonuclease.
9. The method according to Claim 5, wherein said step (c) comprises a protocol selected from the group consisting of: linear PCR; and strand displacement amplification.
10. A method of making a population of target nucleic acids from an initial mRNA sample, said method comprising:
 - (a) generating a mixture of nucleic acids according to the method of Claim 1; and
 - (b) employing said mixture of nucleic acids as primers in a target generation step in which target nucleic acids are produced from said mRNA sample;
whereby said population of target nucleic acids is produced.
11. The method according to Claim 10, wherein said target generation step (b) comprises a template driven primer extension reaction.
12. The method according to Claim 10, wherein said target generation step (b) produces labeled target nucleic acids.
13. A hybridization assay comprising the steps of:
 - (a) generating a set of target nucleic acids according to the method of Claim 10;
 - (b) contacting said set of target nucleic acids with an array of probe nucleic acids under hybridization conditions; and
 - (c) detecting the presence of target nucleic acids hybridized to probe nucleic acids of said array.

14. The assay according to Claim 13, wherein said target nucleic acids are labeled.

15. The assay according to Claim 13, wherein said assay further comprises washing unbound target away from the surface of said array.

21. A method for producing a mixture of nucleic acids, said method comprising:

(a) providing an array of distinct single-stranded probe nucleic acids of differing sequence where each distinct probe present on said array comprises a constant domain and a complement variable domain; wherein said complement variable domain is at the 5' end of said each distinct probe;

(b) hybridizing nucleic acids complementary to said constant domain with said array of single-stranded probe nucleic acids to produce a template array of overhang comprising duplex nucleic acids, wherein each overhang comprising duplex nucleic acid of said array comprises a double-stranded constant region and a single-stranded variable region overhang;

(c) subjecting said template array of overhang comprising duplex nucleic acids to an in vitro transcription protocol to produce a mixture of single stranded nucleic acids of differing sequence; and

(d) separating said mixture of nucleic acids from said template array.

22. A method for producing a mixture of nucleic acids, said method comprising:

(a) providing an array of distinct single-stranded probe nucleic acids of differing sequence where each distinct probe present on said array comprises a constant domain and a complement variable domain; wherein said complement variable domain is at the 5' end of said each distinct probe;

(b) hybridizing nucleic acids complementary to said constant domain with said array of single-stranded probe nucleic acids to produce a template array of overhang comprising duplex nucleic acids, wherein each overhang comprising duplex nucleic acid of said array comprises a double-stranded constant region and a single-stranded variable region overhang;

(c) subjecting said template array of overhang comprising duplex nucleic acids to a linear PCR protocol to produce a mixture of single stranded nucleic acids of differing sequence; and

(d) separating said mixture of nucleic acids from said template array.

23. A method for producing a mixture of nucleic acids, said method comprising:

(a) providing an array of distinct single-stranded probe nucleic acids of differing sequence where each distinct probe present on said array comprises a constant domain and a complement variable domain; wherein said complement variable domain is at the 5' end of said each distinct probe;

(b) hybridizing nucleic acids complementary to said constant domain with said array of single-stranded probe nucleic acids to produce a template array of overhang comprising duplex nucleic acids, wherein each overhang comprising duplex nucleic acid of said array comprises a double-stranded constant region and a single-stranded variable region overhang;

(c) subjecting said template array of overhang comprising duplex nucleic acids to a strand displacement amplification protocol to produce a mixture of single stranded nucleic acids of differing sequence; and

(d) separating said mixture of nucleic acids from said template array.

EVIDENCE APPENDIX

No evidence that qualifies under this heading has been submitted during the prosecution of this application, and as such it is left blank.

RELATED PROCEEDINGS APPENDIX

As stated in the *Related Appeals and Interferences* section above, there are no other appeals or interferences known to Appellants, the undersigned Appellants' representative, or the assignee to whom the inventors assigned their rights in the instant case, which would directly affect or be directly affected by, or have a bearing on the Board's decision in the instant appeal. As such this section is left blank.